The association between the functional PTPN22 1858 C/T and MIF −173 C/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis
- First Online:
- 192 Downloads
The aim of this study was to determine whether the protein tyrosine phosphatase nonreceptor 22 (PTPN22) 1858 C/T (rs2476601) and macrophage migration inhibitory factor (MIF) −173 C/G polymorphisms confer susceptibility to juvenile idiopathic arthritis (JIA).
A meta-analysis was conducted on variant alleles versus common alleles of the PTPN22 1858 C/T and MIF −173 C/G polymorphisms across ten comparative studies, which containing 4,238 JIA patients and 6,012 normal control subjects.
Ten comparative studies, consisting of nine European, and one Turkish population, were included in his meta-analysis. Meta-analysis showed an association between the T allele of the PTPN22 1858 C/T polymorphism and JIA in Europeans [odds ratio (OR) 1.311, 95% confidence interval (CI) 1.205–1.427, P < 1 × 10−8]. In addition, meta-analysis revealed an association between the C allele of the MIF −173 C/G polymorphism and JIA in all subjects (OR 1.482, 95% CI 1.202–1.828, P = 2.3 × 10−4).
This meta-analysis confirms that the PTPN22 1858 C/T polymorphism is associated with JIA susceptibility in Europeans and shows that the MIF −173 C/G polymorphism may be associated with susceptibility to JIA.
KeywordsProtein tyrosine phosphatase nonreceptor 22 Migration inhibitory factor Polymorphism Juvenile idiopathic arthritis Meta-analysis
- 2.Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase. Lyp Blood. 1999;93:2013–24.Google Scholar
- 7.Donn R, Alourfi Z, De Benedetti F, et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:2402–9.PubMedCrossRefGoogle Scholar
- 17.Davey Smith G, Egger M. Meta-analyses of randomised controlled trials. Lancet. 1997; 350:1182.Google Scholar